No Data
No Data
Shanghai Xuerong Bio-Technology (300511.SZ): Intends to repurchase 31.03% equity of Lin Tao Xuerong held by the fund.
On August 5th, Gelunhui reported that Shanghai Xuerong Bio-technology (300511.SZ) held the 12th meeting of the fifth board of directors on August 5, 2024, and passed the Proposal on Repurchasing the Equity of Subsidiaries with 6 votes in favor, 0 votes against and 0 abstentions. According to the arrangements for equity repurchase stipulated in the capital increase and share expansion agreement, the company and Linchuan Xuerong, along with Gansu Industrial Development Investment Fund Co., Ltd. (hereinafter referred to as 'Investment Fund'), signed the 'Agreement on Repurchase and Share Transfer of Linchuan Xuerong Bio-technology Co., Ltd.'s Held by Investment Fund' on August 5th, 2024, with the company repurchasing Linchuan Xuerong held by Investment Fund.
Xuerong Biology (300511.SZ): In 2023, the production of enoki mushrooms was 366,700 tons, and the production of shimeji mushrooms was 81,700 tons
Shanghai Xuerong Bio-Technology (300511.SZ) stated on the investor communication platform that the company's main raw materials include rice bran, corn cob, bran, cottonseed hulls, beer dregs, etc. The company's suppliers are widely distributed and numerous, and there is no reliance on a single supplier. In 2023, the company's production of shiitake mushrooms was 366,700 tons, and the production of enoki mushrooms was 81,700 tons.
Shanghai Xuerong Bio-technology (300511.SZ): focuses on the research and development, factory production, and sales of fresh edible mushrooms.
Shanghai Xuerong Bio-Technology (300511.SZ) stated on the investor interaction platform on June 7th that the company's main business is the research and development, factory cultivation, and sales of fresh edible mushrooms. The company's products are mainly sold through dealers and directly sold to channels such as supermarket systems, chain dining systems, and fresh delivery platforms. The company will continue to actively develop domestic and foreign markets.
Shanghai Xuerong Biotechnology Co.,Ltd.'s (SZSE:300511) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Even After Rising 31% This Past Week, Shanghai Xuerong BiotechnologyLtd (SZSE:300511) Shareholders Are Still Down 50% Over the Past Five Years
Xuerong Biotech (300511.SZ) reported first-quarter results, net profit of 5.2403 million yuan, a year-on-year decrease of 97.65%
Xuerong Biotech (300511.SZ) released its report for the first quarter of 2024. The company achieved operating income during the reporting period...
No Data